Success Metrics

Clinical Success Rate
100.0%

Based on 7 completed trials

Completion Rate
100%(7/7)
Active Trials
6(43%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
4
29%
Ph phase_1
6
43%
Ph phase_2
4
29%

Phase Distribution

6

Early Stage

4

Mid Stage

4

Late Stage

Phase Distribution14 total trials
Phase 1Safety & dosage
6(42.9%)
Phase 2Efficacy & side effects
4(28.6%)
Phase 3Large-scale testing
4(28.6%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

7 of 7 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

6

trials recruiting

Total Trials

14

all time

Status Distribution
Active(6)
Completed(7)
Other(1)

Detailed Status

Completed7
Active, not recruiting5
unknown1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
14
Active
6
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 16 (42.9%)
Phase 24 (28.6%)
Phase 34 (28.6%)

Trials by Status

active_not_recruiting536%
unknown17%
completed750%
recruiting17%

Recent Activity

6 active trials
Showing 5 of 14
completedphase_2

Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants

NCT06737042
active_not_recruitingphase_3

A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Obese/Overweight Subjects

NCT06728124
active_not_recruitingphase_3

A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Subjects With Type 2 Diabetes Mellitus and Poor Blood Glucose Control by Diet and Exercise

NCT06777238
recruitingphase_3

Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects

NCT07150975
active_not_recruitingphase_3

A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus

NCT06778967
View all 14 trials

Clinical Trials (14)

Showing 14 of 14 trials
NCT06737042Phase 2

Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants

Completed
NCT06728124Phase 3

A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Obese/Overweight Subjects

Active Not Recruiting
NCT06777238Phase 3

A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Subjects With Type 2 Diabetes Mellitus and Poor Blood Glucose Control by Diet and Exercise

Active Not Recruiting
NCT07150975Phase 3

Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects

Recruiting
NCT06778967Phase 3

A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus

Active Not Recruiting
NCT07055386Phase 2

A Study to Compare the Efficacy and Safety of GZR102 Injection and GZR18 Injection in Type 2 Diabetes Mellitus

Active Not Recruiting
NCT06256562Phase 2

A Study of GZR18 Injection in Obese/Overweight Patients

Completed
NCT06554054Phase 1

A Study of GZR18 Tablet in Chinese Healthy Subjects

Active Not Recruiting
NCT06548997Phase 1

A Phase I Study of GZR18 Injection in Healthy Subjects

Completed
NCT06548945Phase 1

A Phase I Study of GZR18 Injection in Obese/Overweight Subjects

Completed
NCT06256549Phase 2

A Study of GZR18 Injection in Chinese Patients With Type 2 Diabetes Mellitus

Unknown
NCT06256536Phase 1

A Study of GZR18 Injection in Chinese Obese/Overweight Patients

Completed
NCT06256523Phase 1

A Study of GZR18 Injection in Chinese Adult Patients With Type 2 Diabetes Mellitus (T2DM)

Completed
NCT05328726Phase 1

Single, Ascending Dose, First Time in Human Study for GZR18 in Healthy Subjects

Completed

All 14 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
14